LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)
Close on Nov 17, 2026Market cap $109.97MP/E –Yield –
LENZ Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
LENZ Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$113.91M. For fiscal 2025 it was -$69.17M. The highest annual figure on record is -$8.72M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$69.17M | – |
| FY2024 | Dec 31, 2024 | -$59.39M | – |
| FY2023 | Dec 31, 2023 | -$60.38M | – |
| FY2022 | Dec 31, 2022 | -$87.98M | – |
| FY2021 | Dec 31, 2021 | -$52.85M | – |
| FY2020 | Dec 31, 2020 | -$8.72M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$38.71M | – |
| Q1 FY2026 | Mar 31, 2026 | -$33.58M | – |
| Q4 FY2025 | Dec 31, 2025 | -$33.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.59M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.51M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.08M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.58M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.80M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.09M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.80M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.43M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.22M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.09M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.24M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.59M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.42M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.06M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.49M | – |
See a number that looks wrong?